Key Highlights
- Navan shares surged 19% following an earnings beat and upgraded full-year outlook
- Oracle declined 10% despite impressive quarterly performance, weighed down by concerns over a $40B fundraising plan
- Humacyte shares fell 16% following a share offering priced at $1.05
- PureCycle declined 14% after revealing $395M in capital raising initiatives
- S&P 500 futures climbed 0.60% as investors shook off Wednesday’s AI-driven selloff
Equity futures moved higher Thursday morning as investors sought to recover from the previous session’s steep decline. Wednesday’s downturn was primarily fueled by apprehension surrounding artificial intelligence equities.
Market sentiment brightened following a retreat in crude oil prices. Tension eased after the United States confirmed it had concluded retaliatory military operations against Iran, temporarily reducing concerns about potential escalation.
S&P 500 futures advanced 0.60%, with Dow Jones futures gaining 0.69%. The 10-year Treasury yield declined to 4.526%.
During Wednesday’s trading session, the S&P 500 slid 1.62% while the Dow lost 1.87%. Overnight, Asian equity markets showed mixed performance, with Japan’s Nikkei posting modest gains and China’s Shanghai Composite dipping lower.
Bitcoin appreciated 1.93% to reach $63,095 during early hours. Gold futures decreased 0.64% and Brent crude dropped 1.17%.
Navan Tops the Winners List
Navan emerged as the session’s most impressive performer, with its stock price climbing 19% during pre-market activity.
The corporate travel and expense platform delivered first-quarter financial results that significantly exceeded Wall Street projections. Non-GAAP earnings per share reached $0.08, surpassing analyst estimates by $0.07.
Quarterly revenue totaled $220.3 million, beating the consensus forecast by $15 million.
The company also elevated its full-year projections. Management now anticipates fiscal 2027 revenue ranging from $907 million to $913 million, indicating approximately 30% annual growth.
The profitability outlook received an upward revision as well, with non-GAAP operating income now projected between $76 million and $80 million.
AXT advanced 7.3% in pre-market sessions. Spyre Therapeutics, Coupang, and Tower Semiconductor each recorded increases exceeding 6%.
Oracle Slides Despite Exceeding Projections
Oracle ranked among the session’s most significant decliners, retreating approximately 10% even after delivering robust quarterly figures.
Fourth-quarter revenue expanded 21% on a year-over-year basis to reach $19.2 billion. Adjusted earnings per share of $2.11 exceeded Wall Street expectations.
Cloud infrastructure revenue skyrocketed 93%, while overall cloud revenue climbed 47%. The enterprise software giant also disclosed a $638 billion remaining performance obligation backlog, fueled by substantial AI service contracts.
Oracle projected fiscal 2027 revenue at $90 billion, surpassing analyst consensus estimates.
Despite these positive metrics, the stock faced selling pressure. Primary concerns centered on declining legacy software revenue streams and the company’s announcement to secure $40 billion through debt and equity instruments to finance artificial intelligence data center expansion.
Humacyte plummeted 16% after establishing the pricing for an offering of 47.6 million shares at $1.05 apiece, generating approximately $50 million.
PureCycle tumbled 14% following the disclosure of $395 million in aggregate capital raising activities, encompassing $250 million in convertible debt instruments and an equity offering priced at $8.21 per share.
